Target Audience
This activity is designed for administrative and direct care staff of both CMS & non-CMS accredited healthcare facilities. Staff include physicians, physician assistants, nurses, nurse practitioners, psychologists, administrators, CNAs, occupational, physical & speech therapists, residents & fellows, and social workers who provide care to individuals who reside or receive short-term services in healthcare facilities in NJ. These facilities can include hospitals, skilled nursing homes, assisted living, group homes, memory care centers, and other partnering community care organizations.

Learning Objectives
After participating in ECHO, participants should be better able to:

• Establish standardized emergency response strategies to prevent COVID-19 from entering nursing home facilities via staff, visitors, and residents
• Integrate infection control best practices to prevent greater spread of the virus among patients and staff should an outbreak occur
• Develop an ongoing COVID-19 identification and treatment plan for residents who test positive for COVID-19
• Manage best practice safety measures to protect staff from infection, help staff build confidence in their work and support staff retention
• Recognize and support the emotional & organizational needs of staff, residents, and families
• Coordinate Care that supports NJ State quality and safety goals for nursing homes
• Use the ECHO guided-practice, tele-mentoring model for learning, quality improvement and self-sustaining process improvement

Rutgers RWJMS Project ECHO Planning Committee
Eric Jahn, MD
Brittany Sullivan, MSPH
Ashley Figueroa, MPA
Kathy Dodsworth-Rugani, PhD
Brian Reid, MHA
Ruben Nanez
Martha Hayward
Lindsay Martin, MPSH
Amy Fisher, MHA
Mary Bridgeman, PharmD, BCPS, BCGP

Nursing Home CAN Phase 2 ECHO Session Leaders
• Mary Bridgeman, Pharm D, BCPS, BCGP, Clinical Professor, Rutgers Ernest Mario School of Pharmacy and Clinical Pharmacist, Robert Wood Johnson University Hospital
• Lindsay Martin, MSPH, Instructor, Harvard T.H. Chan School of Public Health, Department of Health Policy and Management; Faculty and Improvement, Advisor, Institute for Healthcare Improvement; Founder, I Squared Consulting Group
• Martha Hayward, IHI Lead, Public and Patient Engagement
• Leone Murphy, APN Supervisor and Nurse Practitioner for the S-COPE Program, Trinitas Regional Medical Center
• Aline Holmes, RN, Clinical Associate Professor Director, Clinical Systems Project, Rutgers University School of Nursing
Accreditation

In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

CME

Rutgers Biomedical and Health Sciences designates this live activity a maximum of 27 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Each session is designated for a maximum of 1.5 AMA PRA Category 1 Credits™.

CNE

This activity is awarded 27 contact hours. (60-minute CH) Each session is awarded a maximum of 1.5 contact hours. Nurses should only claim those contact hours actually spent participating in the activity.

Social Work

This program is approved for social work continuing education hours by Rutgers University Behavioral Health Care in accordance with New Jersey administrative code 13:44G-6.4 and recognized by The New Jersey Board of Social Work Examiners. This program is approved for 27 general social work continuing education hours.

Method of Participation

In order to receive CE credit, participants must register for the ECHO, and complete the evaluation and credit request at the conclusion of each session. Participants will receive one statement of credit from Rutgers Biomedical and Health Sciences at the conclusion of the series.

Peer Review Statement

In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, RBHS has resolved all potential and real conflicts of interest through content review by a non-conflicted, qualified reviewer. This activity was peer-reviewed for relevance, accuracy of content and balance of presentation by the steering committee.

Disclosure Disclaimer

In accordance with the disclosure policies of RBHS and to conform with Joint Accreditation requirements and FDA guidelines, individuals in a position to control the content of this educational activity are required to disclose to the activity participants: 1) the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.

Financial Disclosure Declarations

The following session leaders have no relevant financial relationships to disclose:

Lindsay Martin, MSPH
Martha Hayward
Leone Murphy, APN
Aline Holes, RN

The following planning committee member and session leader has relevant financial relationships to disclose:

Mary Bridgeman, PharmD, BCPS, BCGP- Member, Speakers Bureau: AstraZeneca
The following planning committee members have relevant financial relationships to disclose:

Eric Jahn, MD – Stock shareholder (directly purchased): Proctor & Gamble, Johnson & Johnson
Kathy Dodsworth-Rugani, PhD – Stock shareholder (directly purchased): Johnson & Johnson, Pfizer

The following planning committee members have no relevant financial relationships to disclose:

Ashley Figueroa, MPA
Brittany Sullivan, MSPH
Ruben Nanez
Brian Reid, MHA
Amy Fisher, MHA

**Off-label/Investigational Use Disclosure**

Speakers are required to disclose discussion of off-label/investigational uses of commercial products. These disclosures will be made to the audience at the time of the activity.